Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.47 |
| ▸ | BPTF | Q12830 | 5/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665858 | 0.96 | BPTF (0.48) | HTR6EGFRBPTFTNNI3KGSK3B | |
| Formic Acid SCHEMBL4666109 | 0.90 | HTR6 (0.49) | HTR6EGFRBPTFTNNI3KGSK3B | |
| SCHEMBL4665655 | 0.88 | HTR6 (0.53) | HTR6EGFRBPTF | |
| Formic Acid SCHEMBL4664406 | 0.86 | HTR6 (0.44) | HTR6EGFRBPTFTNNI3KGSK3B | |
| SCHEMBL4664297 | 0.86 | HTR6 (0.54) | HTR6EGFRBPTFGSK3B | |
| SCHEMBL4665741 | 0.86 | BPTF (0.49) | HTR6EGFRBPTF | |
| SCHEMBL4664262 | 0.85 | HTR6 (0.53) | HTR6EGFRBPTF | |
| Formic Acid SCHEMBL4666169 | 0.85 | HTR6 (0.46) | HTR6EGFRBPTF | |
| SCHEMBL4665735 | 0.85 | BPTF (0.50) | HTR6EGFRBPTF | |
| Formic Acid SCHEMBL4665752 | 0.84 | HTR6 (0.43) | HTR6TNNI3KGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | HTR6 826/4885EGFR 279/4885BPTF 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.